Researchers say patient survival is only slightly affected when physicians decide to switch to a second-line series of HIV/AIDS drugs based on clinical symptoms rather than expensive lab tests.
Published in Brief:
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan